Iododerma after high dose urography in an oliguric patient

Very rare adverse reactions to intravascular contrast media: From Kounis to sweet syndrome

Intravascular administration of contrast media may inadvertently result in adverse drug reactions (ADR) including selected hypersensitivity reactions. This review highlights some very rare ADR, aiming to alert imaging physicians to these conditions and to prompt adequate management. This is particularly relevant for Kounis syndrome, an immediate hypersensitivity reaction involving the coronary arteries. The acute management of Kounis syndrome can be challenging, as it requires continued contrast media administration, while balancing the simultaneous coronary reperfusion that requires vasodilatation with anti-allergic treatment that may involve vasoconstrictor agents. For other adverse reactions, referral to a drug allergy specialist is highly recommended to assess causality and identify safe alternatives. CLINICAL RELEVANCE STATEMENT: Cardiologists and radiologists must recognize the key symptoms of these very rare adverse reactions to contrast media to promptly initiate the appropriate therapy and refer patients for allergological evaluation, ideally within 1-6 months after the reaction.

Elimination of Iomeprol in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Objective

To examine the elimination of iomeprol, its safety in clinical use, and its peritoneal permeability in continuous ambulatory peritoneal dialysis (CAPD) patients with variable degrees of residual renal function (RRF).

Design

A nonrandomized comparison study.

Setting

Hospitalized patients in CAPD unit of Chikuho and University Hospitals.

Participants

Fourteen patients treated by CAPD and 6 by hemodialysis (HD).

Interventions

Total dialysate, blood, and 24-hour urine collections were obtained for 4 consecutive days after the administration of iomeprol. A peritoneal equilibration test was performed just before and after the administration of iomeprol.

Measurements

Iomeprol (iodine) concentration was measured. Residual renal function was estimated as the mean of renal creatinine and urea clearances. Dialysate-to-plasma ratios (D/P) of creatinine and iomeprol were also determined.

Results

In all CAPD patients, plasma iomeprol clearance was markedly slow, with a biological half-life ( T1/2) of over 32 hours. However, no patients suffered from any adverse effects, and over 80% of plasma iomeprol was eliminated during the 4-hour HD. The plasma iomeprol elimination rate was significantly higher from 4 hours after the iomeprol administration in CAPD patients with RRF [mean estimated creatinine clearance (CCr) 3.8 mL/min, n = 7] compared to the remaining patients (mean estimated CCr 0.6 mL/min, n = 7); however, T1/2 in patients with RRF was over 24 hours. D/P creatinine was significantly correlated with D/P iomeprol, and peritoneal iomeprol permeability may depend on an individual's peritoneal solute transport properties.

Conclusions

A prolonged elimination rate of iomeprol was documented in our CAPD patients both with and without RRF. A HD procedure or intensive peritoneal dialysis just after the use of iomeprol may be advisable to promptly remove circulating iomeprol.

Clearance and safety of the radiocontrast medium iopamidol in peritoneal dialysis patients

Although the characteristics and safety of radiocontrast media in peritoneal dialysis (PD) patients are not yet well defined, their use in PD patients is considered generally safe. In this study, we evaluated clearance and adverse events of iopamidol in PD patients. We measured the iopamidol concentration in the plasma, dialysate, and urine of 11 patients. Iopamidol clearance from patient plasma was delayed with a half-life of 33.3 h, and the elimination ratio was 83.6% for 96 h. We retrospectively investigated adverse events occurring in a total of 50 stable PD patients who underwent a total of 64 angiographic computed tomography (CT) scans. In 64 angiographic CT scans, two cases of adverse events were observed. Our results suggest that iopamidol can be eliminated by regular PD and careful observation for adverse events are necessary for the safe use of radiocontrast media.

Drug-induced acneiform eruption

Drug-induced acne is a specific subset of acne that usually has some specific features, namely a monomorphic pattern, an unusual location of the lesions beyond the seborrheic areas, an unusual age of onset, a resistance to conventional acne therapy and, of course, the notion of a recent drug introduction. Many drugs can be responsible for such a clinical pattern. Corticosteroids, neuropsychotherapeutic drugs, antituberculosis drugs, and immunomodulating molecules are the more classical drugs associated with induced acne. Recently, new drugs, mainly targeted therapy in the field of oncology, such as epidermal growth factor receptor inhibitors, have been associated with an increased frequency of this adverse effect. Disruption of the culprit drug is rarely mandatory in cases of drug-induced acne. Close cooperation between the dermatologist and medical staff in charge of the patient is an important challenge to achieve optimal management of the initial disease.

Pseudoepitheliomatous hyperplasia: a review

Pseudoepitheliomatous hyperplasia (PEH) is a benign condition, characterized by hyperplasia of the epidermis and adnexal epithelium, closely simulating squamous cell carcinoma. PEH may be present in a number of conditions characterized by prolonged inflammation and/or chronic infection, as well as in association with many cutaneous neoplasms. Herein, we review different inflammatory, infectious, and neoplastic skin diseases, in which florid epidermal hyperplasia is a prominent histopathologic feature, and introduce a systematic approach in the interpretation of PEH.

Preventing complications of radiographic contrast media: is there a role for dialysis?

Nephrologists are often called upon to provide hemodialysis to remove radiographic contrast media in patients with chronic kidney disease (CKD)--usually but not exclusively, those with end-stage renal disease. The reasons for this request vary from concerns over the volume load associated with the administration of a hyperosmolar solution, to the renal and extra-renal toxicities of the contrast itself. Simple calculations demonstrate that the increase in extracellular volume after a typical contrast load is minimal. Data supporting the extra-renal toxicity of contrast in patients maintained on dialysis are lacking. Iodinated contrast agents have molecular weights of 700-1500. This relatively small size as well as their lack of protein binding makes them well suited for removal with extracorporeal renal replacement therapies. Thus, provision of hemodialysis immediately following a contrast load is often utilized in an attempt to prevent further renal damage in patients with advanced stages of CKD. A number of trials have failed to demonstrate that this maneuver is effective. Hemofiltration (HF) has been reported to decrease the risk of acute renal failure in patients with CKD receiving a contrast load, but the studies are methodologically flawed. Therefore, there is currently no sound basis for routinely recommending hemodialysis (or HF) in patients at high risk for contrast media-associated complications.

A practical guide to diagnose lesser-known immediate and delayed contrast media-induced adverse cutaneous reactions

The terms "immediate" and "delayed" adverse reactions induced by contrast media (CM) refer to the reactions' onset but do not provide substantial information concerning the clinical manifestation, the potential risk factors, the treatment modalities, or prevention. Because a variety of different reactions caused by different pathophysiological mechanisms may arise immediately or be delayed after CM injection, and because these need different management, the aim of the present paper is to present the clinical features and to exactly characterize lesser-known cutaneous reactions. A thorough knowledge of the clinical features, their adequate treatment, and, possibly, the subsequent diagnostic procedure for preventing recurrence after reexposure to CM would improve patient management.

Elimination of low-osmolality contrast media by hemodialysis

PURPOSE

To compare the dialyzability and safety of 2 types of low-osmolality contrast media administered to end-stage renal failure patients maintained on regular hemodialysis.

MATERIAL AND METHODS

Of 44 CT examinations, iohexol was used in 22 and ioxaglate in the other 22. Adverse reactions and hemodynamic changes were recorded. Thirty minutes after the beginning of CT investigation, hemodialysis was commenced. Elimination rate and clearance of the contrast media were measured as indices of their dialyzability.

RESULTS

After 4 hours of hemodialysis, 78.4+/-6.5% of iohexol and 72.4+/-6.0% ioxaglate were eliminated. Clearance of iohexol was higher than that of ioxaglate at all sampling times. No severe hemodynamic change nor adverse reaction were observed. Minor reactions were more frequently observed in the ioxaglate group.

CONCLUSION

Iohexol, a nonionic monomeric contrast medium, is more advantageous for hemodialysis patients than ioxaglate, an ionic dimeric contrast medium.

Hydralazine predisposes to acute cutaneous vasculitis following urography with iopamidol

We report a 60-year-old woman with renovascular hypertension who developed a severe cutaneous vasculitis 24 h after the injection of iopamidol during urography. A review of the literature suggests that her concomitant hydralazine therapy probably predisposed her to this reaction, as similar reactions have occurred in systemic lupus erythematosus, and hydralazine can induce a LE-like syndrome. We recommend that urography should be avoided in patients receiving hydralazine.

Vegetating iododerma with underlying systemic diseases: report of three cases

Three patients with vegetating iododerma as a result of potassium iodide therapy are presented. The first patient had polyarteritis nodosa, the second had monoclonal gammopathy of undertermined significance, and the third had multiple myeloma. Vegetating iododerma probably represents an idiosyncratic response to iodides; patients with polyarteritis nodosa and paraproteinemias may be predisposed.

Delayed reactions to urographic contrast media

Reactions to urographic contrast media occurring after the patient had left the department were studied by giving patients a questionnaire to complete. 841 questionnaires were returned (about 80% of those issued). 70% of patients had no delayed reactions and 7% expressed a positive response to urography i.e., found the procedure interesting and not unpleasant; 13% had arm pain, 5% a rash and 14% had a variety of reactions, many of which were the same as those described in iodism. Women had significantly more rashes (7%) than men (4%) and those media containing the meglumine or iodamide ions caused more rashes than other media. Conray 420 caused more arm pain than Conray 280 or the non-ionic media, which would be expected from the known effects on vascular endothelium. Symptoms of iodism were equally common from the various contrast media.

Iododerma due to radiographic contrast medium

Images